|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-11-23
|
|
pubmed:abstractText |
The Intergroup 0116 randomized study showed that postoperative 5-fluorouracil-based chemoradiotherapy improved locoregional control and overall survival in patients with gastric cancer. We hypothesized that these results could be improved further by using a more effective, intensified, and convenient chemotherapy schedule. Therefore, this Phase I-II dose-escalation study was performed to determine the maximal tolerated dose and toxicity profile of postoperative radiotherapy combined with concurrent capecitabine.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1424-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17689023-Adenocarcinoma,
pubmed-meshheading:17689023-Adult,
pubmed-meshheading:17689023-Aged,
pubmed-meshheading:17689023-Antimetabolites, Antineoplastic,
pubmed-meshheading:17689023-Combined Modality Therapy,
pubmed-meshheading:17689023-Deoxycytidine,
pubmed-meshheading:17689023-Drug Administration Schedule,
pubmed-meshheading:17689023-Esophagogastric Junction,
pubmed-meshheading:17689023-Feasibility Studies,
pubmed-meshheading:17689023-Female,
pubmed-meshheading:17689023-Fluorouracil,
pubmed-meshheading:17689023-Humans,
pubmed-meshheading:17689023-Male,
pubmed-meshheading:17689023-Maximum Tolerated Dose,
pubmed-meshheading:17689023-Middle Aged,
pubmed-meshheading:17689023-Radiotherapy Dosage,
pubmed-meshheading:17689023-Stomach Neoplasms
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer.
|
|
pubmed:affiliation |
Department of Radiotherapy of The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. epm.jansen@nki.nl
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
